In melanomas, the anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1 appear to increase while the pro-apoptotic protein Bax decreases with the progression of primary melanoma tumors and melanoma cells and might be involved in resistance to conventional therapies [44]–[46]. This evidence concerns the gene BCL2 and melanoma.